Australian Clinical Labs Ltd (AU:ACL) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Limited has notified the ASX of changes in Director Melinda McGrath’s interests as per listing rules, with McGrath retaining 2,923,331 ordinary shares and experiencing a forfeiture of 247,252 Performance Rights in line with the company’s long-term variable remuneration plan. The rights forfeiture leaves McGrath with 633,584 Performance Rights that are subject to the plan’s vesting provisions.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.